Baker's Yeast, IgE, Serum
Use
This test is useful for establishing a diagnosis of an allergy to baker's yeast by identifying the specific allergen responsible for eliciting signs and symptoms. It can confirm sensitization prior to initiating immunotherapy or investigate specific allergic reactions to various allergens. However, it is not useful for determining if residual clinical sensitivity exists after immunotherapy or where medical management does not depend on allergen specificity.
Special Instructions
Not provided.
Limitations
Individuals with clinically insignificant sensitivity might have measurable IgE antibody levels. Results must be clinically contextualized due to potential false positives in patients with highly elevated serum IgE levels (>2500 kU/L). Testing for IgE antibodies is not recommended in patients previously treated with immunotherapy for residual sensitivity evaluation.
FDA ApprovedNew York Approved
Methodology
Immunoassay (FEIA)
Biomarkers
IgE specific to Baker's Yeast
Protein
LOINC Codes
- 6287-7 - Baker's yeast IgE Qn
- 6287-7 - Baker's yeast IgE Qn
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL for every 5 allergens requested
Minimum Volume
For 1 allergen: 0.3 mL; For more than 1 allergen: (0.05 mL x number of allergens) + 0.25 mL deadspace
Container
Plastic vial, Serum gel (preferred), Red top (acceptable)
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis or lipemia are acceptable.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 90 days |